Myriad Decision Made

A federal appeals court has ruled that genes can be patented, and upheld Myriad Genetics' patents for the BRCA1 and BRCA2 genes, reports The New York Times' Andrew Pollack. Myriad uses the genes as the basis for its BRCAnalysis diagnostic test to detect mutations in the BRCA genes. In March 2010, New York Southern District Court Judge Robert Sweet invalidated the patents and said that genes can't be patented because they are products of nature.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.